Predicting Risk for Incident Heart Failure With Omega-3 Fatty Acids: From MESA
- PMID: 31302044
- DOI: 10.1016/j.jchf.2019.03.008
Predicting Risk for Incident Heart Failure With Omega-3 Fatty Acids: From MESA
Abstract
Objectives: The aim of this study was to determine if plasma eicosapentaenoic acid (EPA) abundance (%EPA) is associated with reduced hazard for primary heart failure (HF) events in the MESA (Multi-Ethnic Study of Atherosclerosis) trial.
Background: Clinical trials suggest that omega-3 polyunsaturated fatty acids (ω3 PUFAs) prevent sudden death in coronary heart disease and HF, but this is controversial. In mice, the authors demonstrated that the ω3 PUFA EPA prevents contractile dysfunction and fibrosis in an HF model, but whether this extends to humans is unclear.
Methods: In the MESA cohort, the authors tested if plasma phospholipid EPA predicts primary HF incidence, including HF with reduced ejection fraction (EF) (EF <45%) and HF with preserved EF (EF ≥45%) using Cox proportional hazards modeling.
Results: A total of 6,562 participants 45 to 84 years of age had EPA measured at baseline (1,794 black, 794 Chinese, 1,442 Hispanic, and 2,532 white; 52% women). Over a median follow-up period of 13.0 years, 292 HF events occurred: 128 HF with reduced EF, 110 HF with preserved EF, and 54 with unknown EF status. %EPA in HF-free participants was 0.76% (0.75% to 0.77%) but was lower in participants with HF at 0.69% (0.64% to 0.74%) (p = 0.005). Log %EPA was associated with lower HF incidence (hazard ratio: 0.73 [95% confidence interval: 0.60 to 0.91] per log-unit difference in %EPA; p = 0.001). Adjusting for age, sex, race, body mass index, smoking, diabetes mellitus, blood pressure, lipids and lipid-lowering drugs, albuminuria, and the lead fatty acid for each cluster did not change this relationship. Sensitivity analyses showed no dependence on HF type.
Conclusions: Higher plasma EPA was significantly associated with reduced risk for HF, with both reduced and preserved EF. (Multi-Ethnic Study of Atherosclerosis [MESA]; NCT00005487).
Keywords: docosahexaenoic acid; eicosapentaenoic acid; hazard ratio; heart failure with preserved ejection fraction; omega-3 fatty acids.
Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Comment in
-
Omega-3 Fatty Acids and Heart Failure: Evidence and Still Open Questions.JACC Heart Fail. 2019 Aug;7(8):662-663. doi: 10.1016/j.jchf.2019.04.007. Epub 2019 Jul 10. JACC Heart Fail. 2019. PMID: 31302045 No abstract available.
Similar articles
-
Fibroblast Growth Factor-23 and Heart Failure With Reduced Versus Preserved Ejection Fraction: MESA.J Am Heart Assoc. 2018 Sep 18;7(18):e008334. doi: 10.1161/JAHA.117.008334. J Am Heart Assoc. 2018. PMID: 30371180 Free PMC article.
-
Associations With Eicosapentaenoic Acid to Arachidonic Acid Ratio and Mortality in Hospitalized Heart Failure Patients.J Card Fail. 2016 Dec;22(12):962-969. doi: 10.1016/j.cardfail.2016.04.017. Epub 2016 Apr 29. J Card Fail. 2016. PMID: 27138463
-
ω3-Polyunsaturated fatty acids for heart failure: Effects of dose on efficacy and novel signaling through free fatty acid receptor 4.J Mol Cell Cardiol. 2017 Feb;103:74-92. doi: 10.1016/j.yjmcc.2016.12.003. Epub 2016 Dec 14. J Mol Cell Cardiol. 2017. PMID: 27986444 Free PMC article. Review.
-
Left ventricular dilation and incident congestive heart failure in asymptomatic adults without cardiovascular disease: multi-ethnic study of atherosclerosis (MESA).J Card Fail. 2014 Dec;20(12):905-11. doi: 10.1016/j.cardfail.2014.09.002. Epub 2014 Sep 16. J Card Fail. 2014. PMID: 25225112 Free PMC article.
-
PUFA Supplementation and Heart Failure: Effects on Fibrosis and Cardiac Remodeling.Nutrients. 2021 Aug 26;13(9):2965. doi: 10.3390/nu13092965. Nutrients. 2021. PMID: 34578843 Free PMC article. Review.
Cited by
-
Qualitative and Quantitative Effects of Fatty Acids Involved in Heart Diseases.Metabolites. 2022 Feb 25;12(3):210. doi: 10.3390/metabo12030210. Metabolites. 2022. PMID: 35323653 Free PMC article. Review.
-
Signaling through Free Fatty Acid Receptor 4 Attenuates Cardiometabolic Disease.Physiology (Bethesda). 2022 Nov 1;37(6):311-322. doi: 10.1152/physiol.00007.2022. Epub 2022 Aug 9. Physiology (Bethesda). 2022. PMID: 35944007 Free PMC article. Review.
-
Epigenetic Therapies for Heart Failure: Current Insights and Future Potential.Vasc Health Risk Manag. 2021 May 24;17:247-254. doi: 10.2147/VHRM.S287082. eCollection 2021. Vasc Health Risk Manag. 2021. PMID: 34079271 Free PMC article. Review.
-
Clinical significance of polyunsaturated fatty acids in the prevention of cardiovascular diseases.Front Nutr. 2022 Oct 6;9:998291. doi: 10.3389/fnut.2022.998291. eCollection 2022. Front Nutr. 2022. PMID: 36276836 Free PMC article. Review.
-
Nutritional and Nutraceutical Support to the Failing Myocardium: A Possible Way of Potentiating the Current Treatment of Heart Failure.Int J Mol Sci. 2024 Nov 14;25(22):12232. doi: 10.3390/ijms252212232. Int J Mol Sci. 2024. PMID: 39596298 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
- N01HC95169/HL/NHLBI NIH HHS/United States
- N01HC95161/HL/NHLBI NIH HHS/United States
- N01HC95168/HL/NHLBI NIH HHS/United States
- N01HC95162/HL/NHLBI NIH HHS/United States
- UL1 TR001420/TR/NCATS NIH HHS/United States
- N01HC95165/HL/NHLBI NIH HHS/United States
- N01HC95167/HL/NHLBI NIH HHS/United States
- N01HC95159/HL/NHLBI NIH HHS/United States
- N01HC95163/HL/NHLBI NIH HHS/United States
- N01HC95164/HL/NHLBI NIH HHS/United States
- UL1 TR000040/TR/NCATS NIH HHS/United States
- N01HC95160/HL/NHLBI NIH HHS/United States
- UL1 TR001079/TR/NCATS NIH HHS/United States
- N01HC95166/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous